CD274 and neoplasm: To investigate whether PDL1-NP-FEXO could boost antitumor efficacy in vivo vs. the free PD-L1 aptamer, CT26 tumor-bearing mice were treated with PBS, free PD-L1 aptamer, PDL1-NP, NP-FEXO, or PDL1-NP-FEXO intraperitoneally every two days for a total of six injections.